Theravance Biopharma Inc.

The big respiratory players will be casting envious glances at the launch of Verona Pharma’s chronic obstructive pulmonary disorder (COPD) drug, Ohtuvayre, which is going from strength to strength. Th

Having delivering a submission for ensifentrine to the desks of US regulators, Verona Pharma plc is now putting in place a strategy designed to give its closely watched chronic obstructive pulmonary

Following the failure of its antibiotic ridinilazole in Clostridium difficile infection in December 2021, Summit Therapeutics plc executed a pivot from anti-infectives to oncology a year later whe

Theravance Biopharma Inc. is jettisoning its JAK inhibitor program and laying off nearly a fifth of its staff. Its second restructuring in two years, it will now concentrate on its marketed in-house